AI Draws New Value from Old Medical Technology - Dr. Jacob Donoghue, Co-Founder & CEO of Beacon Biosignals

In this episode of Raise the Line, we dive into the fascinating story of a very old technology, EEGs, being mined for data using a very new technology, AI, that's changing the way treatments are being developed for disorders of the brain. Joining host Michael Carrese to explain is Dr. Jake Donoghue, co-founder and CEO of Beacon Biosignals, a startup that’s using AI to unlock precision medicine for various neurological, psychiatric and sleep disorders. “We utilize our AI tools to bring quantitative endpoints into clinical trials to see if the drugs are impacting brain activity,” Donoghue explains.  AI’s ability to quickly recognize subtle changes in electrical activity that might otherwise go unnoticed can accelerate the trial process and hopefully, approval of new therapies. Donoghue is also interested in the area of sleep medicine because of its connection to a wide variety of issues including depression, PTSD, Parkinson’s and Alzheimer’s disease. “We think there's a lot of opportunity to bring quantitative insights to this fundamental state that all humans go through and map some of these really robust features of brain activity to increase understanding of disease and health.”

Mentioned in this episode:  https://beacon.bio/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast